-Reuters
Teva Pharmaceutical Lifts Revenue Forecast – Huntington’s And Migraine Drugs Help Q3 Performance
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported Q3 sales of $3.85 billion, beating the consensus of $3.72 billion
Related Posts
Ioneer Stock Gains Following Conditional Loan Commitment From US DoE For Rhyolite Ridge Project
Ioneer Ltd (NASDAQ:IONR) has received a loan of up to $700 million from the U.S. Department of Energy (DOE) Loan Programs…
Costco, Robinhood And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher by around 0.1% on Wednesday. Investors, meanwhile, focused on some notable insider trades.
